From: Cytomegalovirus reactivation and its clinical impact in patients with solid tumors
Gender | Age | Tumor entity | TX setting | Tumor therapy | CMV copies/mL | Assay (specimen) | Kind of co-infection | CMV therapy | Outcome |
---|---|---|---|---|---|---|---|---|---|
f | 59 | Breast | adjuvant | no | 235 | blood | no | no | alive |
m | 59 | SCLC | palliative | CTX | 132 | blood | no | no | alive |
f | 79 | SCLC | palliative | CTX | 34 | blood | HSV-esophagitis | no | alive |
f | 93 | Breast | palliative | anti-hormonal | 120 | blood | no | no | alive |
m | 70 | SCC | adjuvant | CTX/RTX | 62 | blood | no | no | alive |
m | 52 | SCC | palliative | CTX/RTX | 7,650 | blood | no | no | alive |
f | 53 | Breast | palliative | CTX | 8,000 | blood | no | no | alive |
m | 76 | CUP | palliative | CTX | 129 | blood | no | no | alive |
f | 63 | Pancreas | palliative | CTX | 34 | blood | no | no | alive |
m | 65 | Pancreas | palliative | CTX | 3,409 | blood | EBV, candida, pseudomonas | no | death |
m | 85 | Esophagus | palliative | CTX | 4,500 | blood | no | gancyclovir | alive |
f | 65 | Breast/Lung | adjuvant | CTX | 14,000 | blood & BAL | EBV, HSV | gancyclovir | alive |
m | 67 | CUP | palliative | CTX | 18,000 | blood | no | gancyclovir | alive |
f | 72 | CUP | palliative | CTX | 8434 | blood | no | gancyclovir | alive |
f | 63 | Breast | adjuvant | CTX | 476 | blood | no | gancyclovir | alive |
f | 81 | Pancreas | palliative | CTX | 6,000 | blood | Aspergillus, EBV, candida | gancyclovir | death |
f | 69 | Breast | adjuvant | CTX | 6,810 | blood & BAL | Aspergillus, EBV | gancyclovir | death |